Shattuck Labs Announces Participation in Upcoming 23rd Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

Shattuck Labs, Inc. (STTK) to participate in the 23rd Annual Needham Virtual Healthcare Conference. Dr. Taylor Schreiber, the CEO, will present on April 8, 2024, discussing the development of bi-functional fusion proteins for cancer and autoimmune disease treatment.

AUSTIN, TX & DURHAM, NC, April 01, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that company management will participate in the 23rd Annual Needham Virtual Healthcare Conference being held virtually from April 8-11, 2024.

Presentation Details
Conference: 23^rd Annual Needham Virtual Healthcare Conference
Format: Fireside chat with covering analyst Gil Blum, Ph.D.
Presenter: Dr. Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer
Date: April 8, 2024
Time: 1:30-2:10 p.m. ET

A live webcast of the presentation will be available on the Investors section of the Company’s website. A replay of the webcast will be archived for up to 90 days following the presentation date.

About Shattuck Labs, Inc.
Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary Agonist Redirected Checkpoint, (“ARC®”), platform are designed to simultaneously inhibit checkpoint molecules and activate costimulatory molecules with a single therapeutic. The Company’s lead SL-172154 (SIRPα-Fc-CD40L) program, which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in multiple Phase 1 trials. Shattuck has offices in Austin, Texas and Durham, North Carolina. For more information, please visit www.ShattuckLabs.com.

The Company intends to use the investor relations portion of its website as a means of disclosing material non-public information and of complying with disclosure obligations under Regulation FD.

Investor & Media Contact:
Conor Richardson
Vice President of Investor Relations
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com

FAQ

When is Shattuck Labs, Inc. (STTK) participating in the 23rd Annual Needham Virtual Healthcare Conference?

Shattuck Labs, Inc. (STTK) will participate in the 23rd Annual Needham Virtual Healthcare Conference from April 8-11, 2024.

Who will be presenting at the conference from Shattuck Labs, Inc. (STTK)?

Dr. Taylor Schreiber, M.D., Ph.D., the Chief Executive Officer of Shattuck Labs, Inc. (STTK) will be presenting at the conference.

What is the focus of the presentation by Shattuck Labs, Inc. (STTK) at the conference?

The presentation will focus on the development of bi-functional fusion proteins as a new class of biologic medicine for cancer and autoimmune disease treatment.

Where can investors watch the live webcast of the presentation by Shattuck Labs, Inc. (STTK)?

Investors can watch the live webcast of the presentation on the Investors section of Shattuck Labs, Inc. (STTK) website.

How long will the replay of the webcast be available after the presentation date?

The replay of the webcast will be archived for up to 90 days following the presentation date.